Dimitri Dimitriou on Lupuzor | Immupharma | The New Economy Videos

(7:32)

Dimitri F Dimitriou, MSC: \

(6:1econd)

ImmuPharma - Dimitri Dimitrious CEO @ 4TH CLINICAL TRIALS NEXUS MUNICH GERMANY OCT 2019

(46)

ImmuPharma CEO still open to big pharma deal

(6:6)

Dimitri F Dimitriou over de jaarcijfers 2019 van ImmuPharma

(19:24)

ImmuPharma's Dimitriou explains opportunities for Nucant

(4:37)

Interview with ImmuPharma CEO Dimitri Dimitriou at the Frankfurt Stock Exchange

(9:32)

ImmuPharma

(40)

Dimitri Dimitriou

(5:49)

Eleos

(3:21)

Advanced Pharmaceutical Sales Training

(6:13)

lead discovery in drug development

(3:)

Interview with Dr. Richard Goodfellow, CEO of Scancell Holdings PLC (27th Feb 2013)

(6:23)

Lupus : Retour sur 2 études de phase III concernant l'anifrolumab

(19:49)

Prof. Sylviane MULLER - UPR 3572 - CNRS et LabEx Medalis Immunobiologie et thérapie du lupus

(3:7)

JRS : Discussion avec Antoine Bril, Sylviane Muller et Mathieu Gutmann

(21:)

Dimitri Dimitriou

(2:21)

Η επόμενη ημέρα σε οδικούς άξονες, σιδηρόδρομο και αεροδρόμια

(1:57:40)

Герман Клименко, LiveInternet

(43)

The deal about the partnership between ImmuPharma and Avion Pharmaceuticals is on the final stage

(2:48)

How mixed background of ImmuPharma CEO helps to compete with the big pharmaceutical companies

(2:46)

ImmuPharma chair hails “successful” recruitment for Lupuzor trials

(6:53)

Why investors are considering ImmuPharma, ahead of phase III data release

(46:45)

'We have absolutely no side effect profile in Lupuzor at all' says ImmuPharma chairman

(9:47)

Immupharma 'looking forward and planning for success' with Lupuzor

(7:41)

Immupharma PLC assessing best route forward for lead drug Lupuzor

(9:37)

Successful AstraZeneca lupus study bodes well for ImmuPharma's Lupuzor - analyst

(6:)

ImmuPharma Plc | Gallery Suite | Master Investor Show 2017

(9:23)

ImmuPharma: Analyst discusses 'impressive and potentially blockbuster' Lupuzor licensing deal

(8:51)

Immupharma chairman 'delighted' with first significant investment from specialist US funds

(12:27)